Efineptakin alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Efineptakin alfa
Accession Number
DB16395
Description

Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immunology, and infectious disease.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Hyleukin
  • NT-I7
  • Recombinant human IL-7-HYFC
External IDs
  • NT-I7

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
3K3WC6MT6P
CAS number
2026634-47-7

References

General References
  1. NeoImmuneTech: NT-I7 is a Unique T Cell Amplifier. [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentGastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)1
1Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1Not Yet RecruitingTreatmentRecurrent Head and Neck Squamous Cell Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Oral Cavity Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Resectable Oropharyngeal Squamous Cell Carcinoma1
1RecruitingSupportive CareGliomas, Malignant / Lymphopenia1
1RecruitingTreatmentBladder Carcinoma / Carcinoma, Breast / Colorectal Adenocarcinoma1
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2RecruitingTreatmentAny Advanced Solid Tumors / Malignant Neoplasm of Pancreas / Microsatellite Stable Colorectal Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Small Cell Lung Cancer (SCLC) / Triple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentCutaneous Squamous Cell Carcinoma / Melanoma / Neuroendocrine Carcinoma of the Skin1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 23, 2020 09:12 / Updated on January 01, 2021 00:43